Changes in HER3 expression profiles between primary and recurrent gynecological cancers
Yuki Kojima(Asahi General Hospital), Kan Yonemori(National Cancer Centre Japan)
Cited by 12
Related Papers
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study
|The Lancet Oncology|2021|401
Feasibility and utility of a panel testing for 114 cancer‐associated genes in a clinical setting: A hospital‐based study
|Cancer Science|2019|375
First-in-Human Phase 1 Study of MORAb-202, an Antibody–Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-α–Positive Advanced Solid Tumors
|Clinical Cancer Research|2021|97
Trop-2 expression and the tumor immune microenvironment in cervical cancer
|Gynecologic Oncology|2024|16
Therapeutic target biomarkers of patient-derived xenograft models of gastric-type cervical adenocarcinoma
|Gynecologic Oncology Reports|2023|0